Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Activity opens: 04/25/2023
Activity expires: 04/30/2024
Overview:
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
Program Description:
Despite evidence supporting early use of long-acting injectable (LAI) antipsychotics in adults with schizophrenia, LAIs are often initiated late in the course of treatment. This Tweetorial summarizes the key points of discussion between Leslie Citrome, MD, MPH, John Lauriello, MD, and Amber Hoberg, PMHNP-BC comparing data between LAI and OA use in adults with schizophrenia, including hospitalization rates, adherence, relapse risk, and clinical trials. The experts discuss the remaining barriers to implementing LAI treatment, and how to initiate LAI treatment in real-world practice.
Learning Objectives:
After completing this educational activity, you should be able to:
• Examine data comparing the efficacy of LAIAs and oral medications.
• Analyze the clinical trial data and unique considerations of available LAIAs.
• Implement early integration of LAIA therapies in appropriate patients.
Additional details will be posted as soon as information is available.